EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

Emily Pender, Rosalind Hughes, Brian Kirby

JEADV Clinical Practice · 2026-06 · 5 (2) · 373-384

DOI: 10.1002/jvc2.70268 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JEADV Clinical Practice, online erschienen am 18.01.2026. Verfasst von Emily Pender und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed for the treatment of HS. Other biologics and small molecules have been used off‐licence for the treatment of HS, and evidence for their efficacy comes from case series and small clinical trials. The treatment landscape for HS is expanding, and new biologics and small molecules have been investigated in Phase 2 clinical trials. Those with clinically significant effects on disease activity have progressed to, or are planned to progress to, Phase 3 trials. This review discusses those medications under investigation currently, and the current licenced and off licence treatments available in clinical practice. It highlights some of the difficulties that arise in HS research, and their potential impact on the study and licencing of medications for HS.

Zitieren

APA

Pender, E., Hughes, R., & Kirby, B. (2026). New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa. JEADV Clinical Practice, 5(2), 373-384. https://doi.org/10.1002/jvc2.70268

Vancouver

Pender E, Hughes R, Kirby B. New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa. JEADV Clinical Practice. 2026;5(2):373-384. doi:10.1002/jvc2.70268

BibTeX
@article{Pender2026,
  author = {Pender, Emily and Hughes, Rosalind and Kirby, Brian},
  title = {New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa},
  journal = {JEADV Clinical Practice},
  year = {2026},
  volume = {5},
  number = {2},
  pages = {373--384},
  doi = {10.1002/jvc2.70268}
}
Kostenlos starten →